Preliminary results from SpectraCure's prostate treatments
Preliminary results have been reported from the latest patient treatments in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. A very clear treatment effect is seen on MR images in the treatment area, indicating destruction of the tumour, just like previously treated patients with the high drug dose.
In the patients where follow-up of PSA values has been made, very clear reduction of PSA is seen after treatment, with decreases in the range of 50-73%.
"It is very gratifying that we get continued good results," says Johannes Swartling, CTO. "We are also pleased with the good cooperation with the team in London and we look forward to the continuation of the study".
The purpose of SpectraCure's Phase 2 study is to show that the method is safe to use, and that it has clinical effect, with a larger statistic basis than in the Phase 1 study.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: firstname.lastname@example.org, phone: +46(0) 8 503 000 50
This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on May 23th, 2019.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region